Stratatech Corp. has received $3.95 million from a federal defense agency for the next phase of clinical trials of its living human skin substitute product.

The Defense Department’s Armed Forces Institute of Regenerative Medicine will provide the money for tests of the Madison company’s StrataGraft tissue product.

The goal of the phase II trial is to “assess the efficacy of StrataGraft tissue as a true skin substitute in the healing of excised, deep, partial-thickness burns that otherwise would require skin grafting,” the company said in a statement. Previous trials showed Stratatech’s tissue met goals for safety and effectiveness in patients with third-degree burns and other serious skin injuries.

“This type of funding for a clinical trial really demonstrates the uniqueness of this living skin substitute,” said Lynn Allen-Hoffman, Stratatech’s founder and chief executive officer.

The product should help patients with severe burns, wounds from flesh-eating bacteria and other traumatic skin injury, Allen-Hoffman said. It could also benefit military personnel with injuries from improvised explosive devices, she said.

Read the Milwaukee Journal Sentinel story here.